Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : CARB-X
Deal Size : $6.5 million
Deal Type : Funding
LimmaTech Begins Phase 1 Trial for Staphylococcus Aureus Vaccine LBT-SA7
Details : The funding aims to advance the clinical development of LBT-SA7 is the first multivalent vaccine. It is being evaluated for the treatment of skin and soft tissue infections.
Product Name : LBT-SA7
Product Type : Vaccine
Upfront Cash : Undisclosed
February 17, 2025
Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : CARB-X
Deal Size : $6.5 million
Deal Type : Funding
Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LimmaTech Begins Phase 1 Trial for Staphylococcus Aureus Vaccine LBT-SA7
Details : LBT-SA7 is a multivalent toxoid vaccine candidate, which is designed to prevent skin and soft tissue infections caused by the bacterial pathogen, Staphylococcus aureus.
Product Name : LBT-SA7
Product Type : Vaccine
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : GIBF2
Deal Size : $6.0 million
Deal Type : Financing
Bioversys Secures Investment For BV100 Clinical Program in China
Details : The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 11, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : GIBF2
Deal Size : $6.0 million
Deal Type : Financing
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : GSK
Deal Size : $49.5 million
Deal Type : Series C Financing
BioVersys Expands Collaboration with GSK and Extends Series C Round By CHF 12.3M
Details : Proceeds will enable the clinical development of BioVersys’ portfolio, including BV100 (rifabutin), a breakthrough antibiotic targeting Acinetobacter baumannii, a highly resistant bacterial pathogen.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : GSK
Deal Size : $49.5 million
Deal Type : Series C Financing
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inhaled Murepavadin is an antibiotic targeting pseudomonas aeruginosa in cystic fibrosis, non-CF bronchiectasis. It binds to LptD and inhibits lipopolysaccharide transport function of LptD and causes lipopolysaccharide alterations in the bacterium and ul...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AntiBKV is a neutralizing antibody which has been indicated for the treatment of BK virus infections and prevention of BK virus associated complications in kidney transplant recipients.
Product Name : AntiBKV
Product Type : Antibody
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MTX-005
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Memo Therapeutics AG Initiates Phase 1 Clinical Study of MTX-005 Against BK Virus Infection
Details : MTX-005 is a therapeutic antibody candidate that was identified through the screening of a vast number of kidney transplant patients infected with BK virus to find those few with an eradicating antibody response against the virus.
Product Name : MTX-005
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : MTX-005
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAL02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the Agreement, Eagle will be solely responsible for further clinical development of CAL02, consists of liposomes that capture and neutralize bacterial toxins produced by a broad range of Gram-positive and Gram-negative bacteria.
Product Name : CAL02
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 25, 2021
Lead Product(s) : CAL02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
BioVersys Receives €20 Million in EU Financing to Support Development of New Antibiotics
Details : The financing aims to advance the clinical development of Bioversys pipeline including BV100, which is being evaluated for the treatment of Carbapenem-resistant Acinetobacter baumannii Infection.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 04, 2021
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New study shows that Molecular Partners’ tri-specific antiviral DARPin® candidates, ensovibep (MP0420) and MP0423, remain therapeutically active against the known mutations of SARS-CoV-2 including those present in the United Kingdom (UK) and South Afr...
Product Name : MP0420
Product Type : Protein
Upfront Cash : Inapplicable
April 02, 2021
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable